Paul Glasziou

Also affiliated with New South Wales Department of Health

Decision SciencesEconomics, Econometrics and FinanceHealth ProfessionsMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 12 papers. Top paper: “Enhancing the usability of systematic reviews by improving the consideration and description of interventions”.

Enhancing the usability of systematic reviews by improving the consideration and description of interventions

BMJ(2017)10.1136/bmj.j2998

N/A

5.8DataRank · unranked

194 citations

Andrew D. Oxman, David Moher, Toby J Lasserson, Ken Stein, Katy Sutcliffe +7 more

Generating comparative evidence on new drugs and devices after approval

The Lancet(2020)10.1016/s0140-6736(19)33177-0

N/A

3.6DataRank · unranked

89 citations

John P. A. Ioannidis, Peter M. Rothwell, Paul Glasziou, Tianjing Li, Adrian F. Hernandez +4 more

Larger effect sizes in nonrandomized studies are associated with higher rates of EMA licensing approval

Journal of Clinical Epidemiology(2018)10.1016/j.jclinepi.2018.01.011

N/A

2.0DataRank · unranked

42 citations

Paul Glasziou, Farina A. Klocksieben, Tea Reljic, Magali VanDenBergh, Rahul Mhaskar +4 more

US Food and Drug Administration Approvals of Drugs and Devices Based on Nonrandomized Clinical Trials

JAMA Network Open(2019)10.1001/jamanetworkopen.2019.11111

N/A

1.5DataRank · unranked

42 citations

Paul Glasziou, Farina A. Klocksieben, John P. A. Ioannidis, Iain Chalmers, Farina Klocksieben +2 more

Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide

BMJ(2014)10.1136/bmj.g1687

N/A

1.4DataRank · unranked

10293 citations

R. Milne, H. Macdonald, M. Johnston, M. Dixon-Woods, J. C. Wyatt +15 more

GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables

Journal of Clinical Epidemiology(2011)10.1016/j.jclinepi.2010.04.026

N/A

1.4DataRank · unranked

10239 citations

Andrew D. Oxman, Elie A. Akl, Regina Kunz, Jan Brozek, Susan Norris +7 more

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes

New England Journal of Medicine(2008)10.1056/nejmoa0802987

N/A

1.3DataRank · unranked

7380 citations

Stephen MacMahon, John Chalmers, Bruce Neal, Laurent Billot, Mark Woodward +20 more

Why Cochrane should prioritise sharing data

BMJ(2018)10.1136/bmj.k3229

N/A

1.2DataRank · unranked

21 citations

Clive E Adams, Mike Clarke, Laura Amato, Hilda Bastian, Elaine Beller +18 more

Editorial Board

Journal of Clinical Epidemiology(2005)10.1016/s0895-4356(05)00270-2

N/A

0DataRank · unranked

0 citations

Peter Tugwell, David P. Earle, Louis Lasagna, Jan P. Vandenbroucke, Alvan R. Feinstein +49 more

Long-term monitoring in primary care for chronic kidney disease and chronic heart failure: a multi-method research programme

Programme Grants for Applied Research(2021)10.3310/pgfar09100

N/A

0DataRank · unranked

5 citations

Richard Stevens, Jeffrey K Aronson, Amitava Banerjee, Julie Evans, Benjamin G. Feakins +23 more

Referee report. For: The imperative to find the courage to redesign the biomedical research enterprise [version 1; peer review: 1 approved with reservations]

Faculty of 1000 Research Ltd(2021)10.5256/f1000research.57067.r90258

N/A

0DataRank · unranked

0 citations

Paul Glasziou

Approaches to prioritising research for clinical trial networks: a scoping review

Trials(2022)10.1186/s13063-022-06928-z

N/A

0DataRank · unranked

6 citations

Haitham Tuffaha, Vendula Blaya‐Nováková, Jenean Spencer, Carmel M. Hawley, Phil Peyton +12 more